Milestone Pharmaceuticals Inc.

NasdaqGS MIST

Milestone Pharmaceuticals Inc. Price to Sales Ratio (P/S) on December 30, 2024

Milestone Pharmaceuticals Inc. Price to Sales Ratio (P/S) is NA on December 30, 2024, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Milestone Pharmaceuticals Inc. 52-week high Price to Sales Ratio (P/S) is NA on December 30, 2024, which is NA below the current Price to Sales Ratio (P/S).
Milestone Pharmaceuticals Inc. 52-week low Price to Sales Ratio (P/S) is NA on December 30, 2024, which is NA below the current Price to Sales Ratio (P/S).
Milestone Pharmaceuticals Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is NA.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: MIST

Milestone Pharmaceuticals Inc.

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard
Employees	47
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends

Past 5 years